title: Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses.
authors.affiliation: Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.
authors.forename: S
authors.initials: S
authors.lastname: Ingen-Housz-Oro
authors.forename: N
authors.initials: N
authors.lastname: Ortonne
authors.forename: O
authors.initials: O
authors.lastname: Chosidow
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002744:Chlorpheniramine / Q000494:pharmacology / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008407:Mast Cells / Q000187:drug effects / Q000473:pathology; D000069283:Rituximab; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014581:Urticaria / Q000139:chemically induced* / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006634:Histamine H1 Antagonists; C018904:dexchlorpheniramine; D002744:Chlorpheniramine; D000069283:Rituximab